ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

ATE Antibe Therapeutics Inc

0.295
0.00 (0.00%)
01 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Antibe Therapeutics Inc ATE Toronto Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 0.295 08:53:16
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.295
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202410:15BWAntibe Announces Appointment of Receiver
19/4/202407:00BWAntibe Provides Update on CCAA Proceedings
16/4/202416:00BWAntibe Announces TSX Delisting Review
09/4/202418:00BWAntibe Announces Granting of Initial Order Under Companies'..
09/4/202410:25PRNCACanadian Investment Regulatory Organization Trade Resumption..
09/4/202408:44PRNCASuspension de la négociation par l'Organisme canadien de..
09/4/202408:42PRNCACanadian Investment Regulatory Organization Trading Halt -..
09/4/202406:00BWAntibe to File an Application for an Initial Order Under..
01/4/202406:00BWAntibe Announces FDA Clinical Hold on Otenaproxesul and..
20/3/202406:00BWAntibe to Present Otenaproxesul PK/PD Results at the ASRA..
07/3/202406:00BWAntibe to Present Otenaproxesul PK/PD Results at the..
04/3/202406:00BWAntibe Announces Unfavorable Decision in Arbitration With..
14/2/202406:00BWAntibe Reports Q3 2024 Interim Financial and Operating..
01/2/202406:00BWAntibe Extends Early Warrant Exercise Incentive Program
29/12/202306:00BWAntibe Announces Early Warrant Exercise Incentive Program
12/12/202306:00BWAntibe Therapeutics Announces Amendment to Warrant Terms
13/11/202306:00BWAntibe Reports Q2 2024 Interim Financial and Operating..
09/11/202306:00BWAntibe Reports PK Results of First Clinical Study of..
01/11/202306:00BWAntibe Completes First Clinical Study of Otenaproxesul’s New..
18/10/202306:00BWAntibe Initiates First Clinical Study of Otenaproxesul’s New..
28/9/202306:00BWAntibe Receives Approval to Initiate PK/PD Study of..
08/9/202316:00BWAntibe Announces Results of 2023 Annual Meeting
21/8/202314:23PRNCAToronto Stock Exchange, Antibe Therapeutics Inc., View From..
14/8/202306:00BWAntibe Reports Q1 2024 Interim Financial and Operating..
29/6/202306:30BWAntibe Reports 2023 Year-End Results and Business Highlights

Su Consulta Reciente

Delayed Upgrade Clock